NCT03419624View on ClinicalTrials.gov

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 19, 2018

Primary Completion Date

April 1, 2019

Study Completion Date

August 5, 2019

Conditions
ObesityDiabetes Mellitus, Type 2
Interventions
DRUG

Dapagliflozin 10mg

Dapagliflozin 10 mg tablet once daily

DRUG

Exenatide 2 mg [Bydureon]

Exenatide 2 mg injection once weekly

DRUG

Placebo Oral Tablet

Placebo oral tablet once daily

DRUG

Placebo injection

Placebo injection once weekly

DRUG

Insulin

daily Insulin injections

DRUG

Metformin, if taken before

If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.

Trial Locations (4)

20246

University Medical Center Hamburg-Eppendorf, Hamburg

21073

Diabetologische Schwerpunktpraxis Harburg, Hamburg

22607

Gemeinschaftspraxis für Innere Medizin und Diabetologie, Hamburg

23758

Diabeteszentrum Oldenburg, Oldenburg

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER